/PRNewswire/ Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on.
Innocan Pharma Corporation: Innocan Pharma Reports Q2 2023 Results Including US$2.706M Increase in Revenues Compared to Q2, 2022 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company specializing in innovative wellness products, today unveiled the successful results of a controlled efficacy trial (the "Trial") of their diabetic foot relief cream (the "Product").
Innocan Pharma Corporation: Innocan Pharma Announces Promising Successful Results in Efficacy Trial of Diabetic Foot Relief Treatment finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
HERZLIYA, Israel and CALGARY, AB, Aug. 15, 2023 /CNW/ Innocan Pharma Corporation (CSE:INNO) (FSE: IP4) (OTCQB:INNPF) (the "Company" or "Innocan") a pharmaceutical technology company specializing in